IL159225A0 - Human monoclonal antibodies to epidermal growth factor receptor (egfr) - Google Patents

Human monoclonal antibodies to epidermal growth factor receptor (egfr)

Info

Publication number
IL159225A0
IL159225A0 IL15922502A IL15922502A IL159225A0 IL 159225 A0 IL159225 A0 IL 159225A0 IL 15922502 A IL15922502 A IL 15922502A IL 15922502 A IL15922502 A IL 15922502A IL 159225 A0 IL159225 A0 IL 159225A0
Authority
IL
Israel
Prior art keywords
egfr
growth factor
monoclonal antibodies
factor receptor
epidermal growth
Prior art date
Application number
IL15922502A
Other languages
English (en)
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Publication of IL159225A0 publication Critical patent/IL159225A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15922502A 2001-06-13 2002-06-13 Human monoclonal antibodies to epidermal growth factor receptor (egfr) IL159225A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29817201P 2001-06-13 2001-06-13
PCT/US2002/018748 WO2002100348A2 (fr) 2001-06-13 2002-06-13 Anticorps monoclonaux humains diriges contre le recepteur de facteur de croissance epidermique (egfr)

Publications (1)

Publication Number Publication Date
IL159225A0 true IL159225A0 (en) 2004-06-01

Family

ID=23149369

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15922502A IL159225A0 (en) 2001-06-13 2002-06-13 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
IL159225A IL159225A (en) 2001-06-13 2003-12-07 Human monoclonal antibodies to epidermal growth factor receptor (egfr)

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL159225A IL159225A (en) 2001-06-13 2003-12-07 Human monoclonal antibodies to epidermal growth factor receptor (egfr)

Country Status (16)

Country Link
US (1) US7247301B2 (fr)
EP (1) EP1417232B1 (fr)
JP (2) JP4298498B2 (fr)
KR (2) KR20090125840A (fr)
CN (2) CN1966525A (fr)
AU (1) AU2002345673B2 (fr)
BR (1) BRPI0210405B8 (fr)
CA (1) CA2450285C (fr)
CZ (1) CZ200438A3 (fr)
HK (1) HK1064685A1 (fr)
HU (1) HUP0600225A3 (fr)
IL (2) IL159225A0 (fr)
MX (1) MXPA03011365A (fr)
NZ (1) NZ530212A (fr)
RU (1) RU2335507C2 (fr)
WO (1) WO2002100348A2 (fr)

Families Citing this family (259)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
BR0010524A (pt) * 1999-05-14 2002-05-28 Imclone Systems Inc Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
AU9500201A (en) * 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
WO2002092771A2 (fr) 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Proteines de liaison specifiques et utilisations associees
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
JP4303105B2 (ja) * 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050158296A1 (en) 2002-01-11 2005-07-21 Starr Christopher M. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20090042291A1 (en) * 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
ES2368733T3 (es) * 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
AU2003290330A1 (en) * 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
CA2450289A1 (fr) * 2003-03-20 2005-05-19 Imclone Systems Incorporated Methode de production d'un anticorps ciblant le recepteur du facteur de croissance epidermique
EP1622941A2 (fr) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Procede de production d'un anticorps contre le recepteur du facteur de croissance epidermique
EP2395016A3 (fr) 2003-05-30 2012-12-19 Merus B.V. Conception et utilisation de régions variables appariées de molécules de liaison spécifiques
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
GB0324368D0 (en) * 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP1737971B1 (fr) 2004-01-20 2017-08-16 Merus N.V. Mélanges de proteines de liason
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
ES2387809T3 (es) * 2004-03-19 2012-10-02 Imclone Llc Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
EP1786918A4 (fr) * 2004-07-17 2009-02-11 Imclone Systems Inc Nouveau anticorps bispecifique tetravalent
HUE034335T2 (en) 2004-07-22 2018-02-28 Kingdon Craig R binding molecule
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
DK2325207T3 (en) 2004-11-12 2017-06-06 Xencor Inc Fc variants with altered binding to FcRn
ES2755976T3 (es) * 2005-02-07 2020-04-24 Roche Glycart Ag Moléculas de unión a antígeno que se unen a EGFR, vectores que las codifican y usos de las mismas
CN100362018C (zh) * 2005-03-02 2008-01-16 上海张江生物技术有限公司 重组抗egfr单克隆抗体
KR101433381B1 (ko) 2005-03-23 2014-10-02 젠맵 에이/에스 다발성 골수종의 치료를 위한 ｃｄ38에 대한 항체
US20060257317A1 (en) * 2005-05-04 2006-11-16 Duke University Combination therapy in the treatment of cancer
BRPI0611445A2 (pt) * 2005-05-09 2010-09-08 Glycart Biotechnology Ag molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica
JP5215180B2 (ja) 2005-06-20 2013-06-19 メダレックス インコーポレーティッド Ｃｄ１９抗体およびその使用法
US7449442B2 (en) * 2005-07-12 2008-11-11 Children's Medical Center Corporation EGFR inhibitors promote axon regeneration
SG164379A1 (en) 2005-07-21 2010-09-29 Genmab As Potency assays for antibody drug substance binding to an fc receptor
ES2539250T3 (es) 2005-07-25 2015-06-29 Emergent Product Development Seattle, Llc Reducción de células B mediante el uso de moléculas de unión específica a CD37 y de unión específica a CD20
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5376948B2 (ja) * 2005-09-13 2013-12-25 ナショナル リサーチ カウンシル オブ カナダ 腫瘍細胞活性を調節する方法及び組成物
EP1931709B1 (fr) 2005-10-03 2016-12-07 Xencor, Inc. Variants de fc dotés de propriétés de liaison aux récepteurs fc optimisées
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
AU2006321364B2 (en) * 2005-12-01 2011-11-10 Domantis Limited Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
JP5401639B2 (ja) 2005-12-08 2014-01-29 メダレックス エル．エル．シー． タンパク質チロシンキナーゼ７（ｐｔｋ７）に対するヒトモノクローナル抗体およびそれらの使用
CN101058609B (zh) * 2006-05-26 2011-04-13 神州细胞工程有限公司 人源抗体及其表达
SG172698A1 (en) 2006-06-12 2011-07-28 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function
EP2046383B1 (fr) 2006-07-04 2014-11-19 Genmab A/S Molécules de liaison à cd20 pour le traitement de copd
AR062223A1 (es) * 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
JP5476122B2 (ja) 2006-09-26 2014-04-23 ゲンマブ エー／エス Ｃｄ３８発現腫瘍の併用処置法
CA2665567C (fr) * 2006-10-06 2012-07-03 Amgen Inc. Formulations stables
CL2007002881A1 (es) * 2006-10-20 2008-05-09 Amgen Inc Formulacion estable que comprende un tampon con un ph de aproximadamente 4 y menos de 6, un cation divalente de 5-150 mm, un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor de crecimiento epidermico; y metodo
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
EP2486928A1 (fr) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Procédé pour le traitement des amyloses
CN104151430A (zh) * 2007-03-01 2014-11-19 西福根有限公司 重组抗表皮生长因子受体抗体组合物
JP5618549B2 (ja) 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
WO2008119565A2 (fr) * 2007-04-03 2008-10-09 Micromet Ag Domaine de liaison spécifique d'espèces croisées
WO2008119566A2 (fr) * 2007-04-03 2008-10-09 Micromet Ag Éléments de liaison bispécifiques spécifiques d'espèces croisées
EP2615175B1 (fr) 2007-05-31 2018-08-08 Genmab A/S Anticorps humains monovalents
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
KR20100040840A (ko) * 2007-06-06 2010-04-21 도만티스 리미티드 폴리펩티드，항체 가변 도메인 및 길항제
US20100322939A1 (en) * 2007-06-21 2010-12-23 Genmab A/S Novel methods for treating egfr-associated tumors
ES2609915T3 (es) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
WO2009030239A1 (fr) * 2007-09-06 2009-03-12 Genmab A/S Nouveaux procédés et anticorps destinés au traitement du cancer
BRPI0821604B1 (pt) 2007-12-26 2021-09-21 Xencor, Inc Polipeptídeo isolado compreendendo um fc variante de polipeptídeo de fc de igg humano, método para produzir o mesmo e uso de anticorpo
JP6014706B2 (ja) * 2008-02-14 2016-10-25 株式会社イーベック ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物
AU2009234389B2 (en) * 2008-04-10 2014-08-21 Cell Signaling Technology, Inc. Compositions and methods for detecting EGFR mutations in cancer
SI2132228T1 (sl) 2008-04-11 2011-10-28 Emergent Product Dev Seatle CD37 imunoterapevtik in kombinacija z njegovim bifunkcionalnim kemoterapevtikom
KR20110014607A (ko) 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
SG191639A1 (en) * 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
RU2010153578A (ru) * 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
CN101602808B (zh) * 2008-06-12 2012-06-20 上海市肿瘤研究所 特异性结合蛋白及其使用
SG192489A1 (en) 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
AU2013202419B2 (en) * 2008-07-16 2014-11-27 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and uses thereof
AU2009287163B2 (en) 2008-08-29 2014-11-13 Les Laboratoires Servier Recombinant anti-Epidermal Growth Factor Receptor antibody compositions
BRPI0917315B8 (pt) * 2008-11-07 2021-05-25 Galaxy Biotech Llc anticorpo monoclonal, seu uso e composição farmacêutica o compreendendo
AU2009322236B2 (en) * 2008-12-04 2013-11-07 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
NZ594514A (en) * 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
RU2012112550A (ru) 2009-09-01 2013-10-10 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
KR101108642B1 (ko) * 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
WO2011047262A2 (fr) 2009-10-15 2011-04-21 Abbott Laboratories Immunoglobulines à deux domaines variables et utilisations afférentes
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN101875696B (zh) * 2009-11-11 2012-02-08 中国人民解放军军事医学科学院生物工程研究所 一种抗体及其制备方法与应用
CN101875695B (zh) * 2009-11-11 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 一种抗体及其编码基因与应用
CA2776513C (fr) 2009-11-24 2017-08-01 Alethia Biotherapeutics Inc. Anticorps anti-clusterine et fragments de liaison de l'antigene et leur utilisation dans la reduction du volume d'une tumeur
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
EP2552967A4 (fr) 2010-04-02 2014-10-08 Amunix Operating Inc Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser
EP2558494B1 (fr) 2010-04-15 2018-05-23 AbbVie Inc. Protéines de liaison à la bêta amyloïde
BR112012026766B1 (pt) 2010-04-20 2021-11-03 Genmab A/S Métodos in vitro para gerar um anticorpo igg heterodimérico, para a seleção de um anticorpo biespecífico, vetor de expressão, anticorpo igg heterodimérico, composição farmacêutica, e, uso de um anticorpo igg heterodimérico
WO2011133886A2 (fr) † 2010-04-23 2011-10-27 Genentech, Inc. Production de protéines hétéromultimères
ES2635594T3 (es) 2010-05-14 2017-10-04 Abbvie Inc. Proteínas de unión a IL-1
WO2011162904A2 (fr) * 2010-05-24 2011-12-29 Marek Malecki Biomarqueurs à domaines multiples pour la détection, le diagnostic et la thérapie du cancer
US9862769B2 (en) 2010-05-27 2018-01-09 Genmab A/S Monoclonal antibodies against HER2
WO2011156617A2 (fr) 2010-06-09 2011-12-15 Aveo Pharmaceuticals, Inc. Anticorps anti-egfr
JP6093696B2 (ja) 2010-06-09 2017-03-08 ゲンマブ エー／エス ヒトｃｄ３８に対する抗体
CN103052649B (zh) 2010-07-29 2015-12-16 Xencor公司 具有修改的等电点的抗体
PE20131412A1 (es) 2010-08-03 2014-01-19 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
CA2809433A1 (fr) 2010-08-26 2012-03-01 Abbvie Inc. Immunoglobulines a deux domaines variables et leurs utilisations
KR101273918B1 (ko) * 2010-09-17 2013-06-13 강원대학교산학협력단 인간 항-상피세포성 성장인자수용체 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물
WO2012047225A2 (fr) * 2010-10-08 2012-04-12 The General Hospital Corporation Méthodes de traitement de la fibrose hépatique et de la pré-cirrhose par inhibiteurs du récepteur des facteurs de croissance épidermique
CN103298489A (zh) 2010-10-29 2013-09-11 伊缪诺金公司 新型egfr结合分子及其免疫偶联物
CN103328505B (zh) * 2010-10-29 2015-12-02 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
SG10201604699VA (en) 2010-12-21 2016-07-28 Abbvie Inc Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
AU2012239997A1 (en) * 2011-04-07 2013-10-17 Amgen Inc. Novel EGFR binding proteins
CN102262155B (zh) * 2011-04-12 2013-10-09 百泰生物药业有限公司 重组人表皮生长因子生物学活性测定方法及其应用
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
WO2012143523A1 (fr) 2011-04-20 2012-10-26 Genmab A/S Anticorps bispécifiques contre her2
JP2014515753A (ja) 2011-04-21 2014-07-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用
JP6208658B2 (ja) 2011-07-05 2017-10-04 バイオアシス テクノロジーズ インコーポレイテッド ｐ９７−抗体結合体および使用方法
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CA2842492A1 (fr) 2011-08-05 2013-02-14 Bioasis Technologies, Inc. Fragments de p97 avec activite de transfert
BR112014007382A2 (pt) 2011-09-30 2017-04-04 Regeneron Pharma anticorpos anti-erbb3 e seus usos
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
ES2739808T3 (es) 2011-10-27 2020-02-04 Genmab As Producción de proteínas heterodiméricas
WO2013071058A1 (fr) * 2011-11-09 2013-05-16 The Uab Research Foundation Anticorps her3 et utilisations de ceux-ci
SG11201402343SA (en) 2011-11-21 2014-06-27 Immunogen Inc Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
PL2782598T3 (pl) * 2011-11-23 2021-03-08 In3Bio Ltd. Rekombinowane białka i ich zastosowania terapeutyczne
SG11201402536PA (en) 2011-11-23 2014-06-27 Medimmune Llc Binding molecules specific for her3 and uses thereof
CN103172741B (zh) * 2011-12-20 2018-04-27 智翔（上海）医药科技有限公司 全人源抗egfr抗体
MX2014008101A (es) 2011-12-30 2014-09-25 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17.
US20150231220A1 (en) * 2012-03-27 2015-08-20 Mogam Biotechnology Research Institute Epitopes of epidermal growth factor receptor surface antigen and use thereof
WO2013157953A1 (fr) 2012-04-20 2013-10-24 Merus B.V. Procédés et moyens de production de molécules de type ig
JP6441792B2 (ja) * 2012-05-17 2018-12-19 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｅｇｆｒに結合する抗原結合蛋白質
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
EP3505534A1 (fr) 2012-06-08 2019-07-03 Sutro Biopharma, Inc. Anticorps comprenant des résidus d'acides aminés non endogènes spécifiques d'un site, leurs procédés de préparation et leurs procédés d'utilisation
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
PT2869845T (pt) * 2012-07-06 2019-12-09 Genmab Bv Proteína dimérica com mutações triplas
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
US9932565B2 (en) 2012-07-31 2018-04-03 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
SI2890402T1 (sl) 2012-08-31 2019-07-31 Sutro Biopharma, Inc. Modificirane aminokisline vsebujoče acido skupino
WO2014064682A1 (fr) * 2012-10-24 2014-05-01 Yeda Research And Development Co. Ltd. Combinaisons d'anticorps ciblant les récepteurs du facteur de croissance épidermique pour traiter le cancer
WO2014071074A2 (fr) 2012-11-01 2014-05-08 Abbvie Inc. Immunoglobulines à domaine variable double anti-vegf/dll4 et leurs utilisations
CN102993305B (zh) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 人源抗人表皮生长因子受体抗体及其编码基因与应用
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
DK3447069T3 (da) 2012-11-21 2020-11-16 Janssen Biotech Inc Bispecifikke egfr/c-met-antistoffer
EA201500741A1 (ru) 2013-01-10 2016-01-29 Генмаб Б.В. ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
SI2943511T1 (sl) 2013-01-14 2020-01-31 Xencor, Inc. Novi heterodimerni proteini
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
WO2014113510A1 (fr) 2013-01-15 2014-07-24 Xencor, Inc. Elimination rapide de complexes antigéniques à l'aide de nouveaux anticorps
RU2528414C1 (ru) 2013-01-25 2014-09-20 Закрытое Акционерное Общество "Фарм-Синтез" Циклический октапептид, радиофармацевтическое средство на его основе и способ применения радиофармацевтического средства для получения лекарственных (фармацевтических) средств для лечения новообразований, экспрессирующих соматостатиновые рецепторы
CA2906003C (fr) 2013-03-13 2021-07-06 Bioasis Technologies Inc. Fragments de p97 et leurs utilisations
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP2970459A2 (fr) 2013-03-15 2016-01-20 AbbVie Inc. Protéines de liaison spécifiques à domaines variables doubles dirigées contre il -1beta et il -17
WO2014141192A1 (fr) 2013-03-15 2014-09-18 Erasmus University Medical Center Génération d'anticorps à chaînes lourdes uniquement
DK2970486T3 (en) 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
RU2652880C2 (ru) * 2013-04-07 2018-05-03 Дженрикс (Шанхай) Байофармасертикал Ко., Лтд. Антитело против рецептора эпидермального фактора роста
EP3019522B1 (fr) 2013-07-10 2017-12-13 Sutro Biopharma, Inc. Anticorps comprenant plusieurs résidus d'acides aminés non naturels site-spécifiques, des procédés permettant leur préparation et leurs méthodes d'utilisation
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
EP3044236A2 (fr) 2013-09-12 2016-07-20 Halozyme, Inc. Anticorps anti-récepteur du facteur de croissance épidermique modifiés et procédés pour les utiliser
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
EP3055298B1 (fr) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés
EP3086814B1 (fr) 2013-12-23 2020-06-24 Bayer Pharma Aktiengesellschaft Conjugués de liants (conjugué anticorps-médicament) comprenant des inhibiteurs de la protéine kinésine du fuseau
WO2015117121A1 (fr) 2014-02-03 2015-08-06 Bioasis Technologies, Inc. Protéines hybrides p97
US10392605B2 (en) 2014-02-19 2019-08-27 Bioasis Technologies Inc. P97-IDS fusion proteins
SG10202008629XA (en) 2014-03-28 2020-10-29 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
CA2943890A1 (fr) 2014-05-01 2015-11-05 Bioasis Technologies, Inc. Conjugues p97-polynucleotides
KR102603417B1 (ko) 2014-05-06 2023-11-20 제넨테크, 인크. 포유동물 세포를 사용한 이종다량체 단백질의 생산
US20170216403A1 (en) 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
CN107073116A (zh) 2014-10-23 2017-08-18 依奈特制药公司 使用抗nkg2a试剂治疗癌症
NZ732144A (en) 2014-11-26 2020-04-24 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
AU2015353416C1 (en) 2014-11-26 2022-01-27 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3233907B1 (fr) 2014-12-19 2021-03-03 Genmab A/S Protéines hétérodimères bispécifiques de rongeurs
EP3237449A2 (fr) 2014-12-22 2017-11-01 Xencor, Inc. Anticorps trispécifiques
WO2016141387A1 (fr) 2015-03-05 2016-09-09 Xencor, Inc. Modulation de lymphocytes t avec des anticorps bispécifiques et des hybrides fc
WO2016171365A1 (fr) * 2015-04-23 2016-10-27 신일제약주식회사 Fragment fab se liant spécifiquement à l'egfr
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN114917361A (zh) 2015-06-22 2022-08-19 拜耳医药股份有限公司 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc）
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
WO2017005649A1 (fr) 2015-07-09 2017-01-12 Genmab A/S Anticorps bispécifiques et multispécifiques et procédé pour l'isolement de ceux-ci
TWI744247B (zh) 2015-08-28 2021-11-01 美商亞穆尼克斯製藥公司 嵌合多肽組合體以及其製備及使用方法
KR20180053322A (ko) 2015-09-21 2018-05-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
WO2017060322A2 (fr) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Conjugué anticorps-médicament (adc) inhibiteur de ptefb
AU2016358296B2 (en) * 2015-11-19 2020-05-21 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
WO2017161206A1 (fr) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugués contenant des anticorps à activité conditionnelle ou des fragments de liaison à un antigène associés, et procédés d'utilisation
CN108883195A (zh) 2016-03-24 2018-11-23 拜耳制药股份公司 具有酶促可裂解基团的细胞毒性活性物质的前药
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
KR20230054508A (ko) 2016-06-14 2023-04-24 젠코어 인코포레이티드 이중특이적 체크포인트 억제제 항체
CA3027445A1 (fr) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Conjugues anticorps-medicament specifiques (adc) avec inhibiteurs de ksp et des anticorps anti-cd123
US11098107B2 (en) 2016-06-15 2021-08-24 Sutro Biopharma, Inc. Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
CN116063545A (zh) 2016-06-28 2023-05-05 Xencor股份有限公司 结合生长抑素受体2的异源二聚抗体
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP7273453B2 (ja) 2016-10-14 2023-05-15 ゼンコア インコーポレイテッド ＩＬ－１５／ＩＬ－１５ＲアルファＦｃ融合タンパク質およびＰＤ－１抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質
EP3558387B1 (fr) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Conjugués anticorps-principe actif (adc) spécifiques renfermant des inhibiteurs de ksp
KR102556826B1 (ko) 2016-12-21 2023-07-18 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
CA3047491A1 (fr) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Promedicaments de principes actifs cytotoxiques contenant des groupes divisibles par voie enzymatique
EP3559047A1 (fr) 2016-12-23 2019-10-30 Novartis AG Anticorps de facteur xi et méthodes d'utilisation
MX2019009346A (es) 2017-02-10 2019-10-02 Genmab Bv Variantes de polipeptidos y usos de los mismos.
WO2018160754A2 (fr) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Protéine monovalente inductible de fixation d' antigène
IL300964A (en) 2017-05-12 2023-04-01 Harpoon Therapeutics Inc mesothelin binding proteins
JP2020529832A (ja) 2017-06-30 2020-10-15 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
EA202090739A1 (ru) 2017-10-13 2020-09-07 Харпун Терапьютикс, Инк. Белки, связывающие антиген созревания в-клеток
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR20200085828A (ko) 2017-11-08 2020-07-15 젠코어 인코포레이티드 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
WO2019195959A1 (fr) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Polythérapie pour cancers à mutation de braf
JP2021520829A (ja) 2018-04-18 2021-08-26 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
EP3781599A1 (fr) 2018-04-18 2021-02-24 Xencor, Inc. Protéines de fusion hétérodimères ciblant pd-1 contenant des protéines de fusion fc d'il-15/il-15ra, domaines de liaison à l'antigène pd-1 et utilisations associées
WO2019243626A1 (fr) 2018-06-22 2019-12-26 Genmab A/S Procédé de production d'un mélange contrôlé d'au moins deux anticorps différents
BR112021005769A2 (pt) 2018-09-25 2021-07-06 Harpoon Therapeutics Inc proteínas de ligação a dll3 e métodos de uso
EP3856763A1 (fr) 2018-09-28 2021-08-04 Massachusetts Institute of Technology Molécules immunomodulatrices localisées dans le collagène et leurs procédés
US11358999B2 (en) 2018-10-03 2022-06-14 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
CN113330033A (zh) 2018-12-26 2021-08-31 先天制药公司 白细胞免疫球蛋白样受体2中和性抗体
EP3914289A1 (fr) 2019-01-23 2021-12-01 Massachusetts Institute of Technology Schéma posologique de dosage d'immunothérapie combinée pour un blocage de points de contrôle immunitaires
WO2020180726A1 (fr) 2019-03-01 2020-09-10 Xencor, Inc. Anticorps hétérodimères qui se lient à enpp3 et cd3
CN114269749A (zh) 2019-06-10 2022-04-01 苏特罗生物制药公司 5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物
US11246906B2 (en) 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
WO2020257235A1 (fr) 2019-06-17 2020-12-24 Sutro Biopharma, Inc. Dérivés de 1-(4-(aminométhyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinoléin-4-amine et composés apparentés en tant qu'agonistes du récepteur 7/8 de type toll (tlr), ainsi que des conjugués anticorps-médicament de ceux-ci destinés à être utilisés dans la thérapie et le diagnostic du cancer
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質－金属水酸化物錯体およびその方法
AU2020329881A1 (en) * 2019-08-09 2022-03-24 A2 Biotherapeutics, Inc. Cell-surface receptors responsive to loss of heterozygosity
BR112022010537A2 (pt) 2019-12-02 2022-08-16 Celgene Corp Terapia para o tratamento do câncer
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
EP4143234A4 (fr) 2020-04-26 2024-07-17 Biocytogen Pharmaceuticals Beijing Co Ltd Immunoglobulines modifiées
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
EP3954393A1 (fr) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Polythérapies pour administration à travers la barrière sang/cerveau
JP2023538115A (ja) 2020-08-20 2023-09-06 エー２ バイオセラピューティクス， インコーポレイテッド Ｃｅａｃａｍ陽性がんを治療するための組成物及び方法
CA3188862A1 (fr) 2020-08-20 2022-02-24 Carl Alexander Kamb Compositions et methodes de traitement de cancers positifs a la mesotheline
WO2022103983A2 (fr) 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Composés de fluorénylméthyloxycarbonyle et de fluorénylméthylaminocarbonyle, conjugués protéines associés et méthodes d'utilisation
KR20230156079A (ko) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Cd3과 cldn6에 결합하는 이종이량체 항체
WO2022192586A1 (fr) 2021-03-10 2022-09-15 Xencor, Inc. Anticorps hétérodimères qui se lient au cd3 et au gpc3
TW202308689A (zh) * 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物
KR102415292B1 (ko) 2022-04-04 2022-07-01 (주)청수 고농도 복합 악취 처리시스템
WO2024006272A1 (fr) 2022-06-27 2024-01-04 Sutro Biopharma, Inc. CHARGES UTILES DE LIEUR β-GLUCURONIDE, LEURS CONJUGUÉS PROTÉIQUES ET MÉTHODES ASSOCIÉES
WO2024015229A1 (fr) 2022-07-15 2024-01-18 Sutro Biopharma, Inc. Charges utiles-lieurs clivables par une protéase/enzyme et conjugués protéiques
WO2024097940A1 (fr) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Thérapie de traitement du cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5470571A (en) * 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US5459061A (en) * 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
US5218090A (en) * 1990-06-12 1993-06-08 Warner-Lambert Company EGF receptor truncates
US5874299A (en) * 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH06509563A (ja) * 1991-07-05 1994-10-27 セラゲン・インコーポレイテッド 炎症性関節炎の治療用の表皮細胞成長因子受容体を標的とする分子
EP0586002B1 (fr) 1992-08-18 2000-01-19 CENTRO de IMMUNOLOGIA MOLECULAR Anticorps monoclonaux contre le récepteur du facteur épidermique de croissance, cellules et méthodes pour leur préparation et compositions qui les contiennent
DE4337197C1 (de) * 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
IT1271461B (it) * 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
SK283889B6 (sk) * 1994-03-17 2004-04-06 Merck Patent Gmbh Jednoreťazcové fragmenty protilátok a protilátky proti receptoru epidermálneho rastového faktoru, spôsob ich prípravy a farmaceutický prostriedok, ktorý ich obsahuje
ES2167391T3 (es) 1994-09-16 2002-05-16 Merck Patent Gmbh Inmunoconjugados ii.
US6538114B1 (en) * 1996-04-19 2003-03-25 Karolina Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
US5708156A (en) * 1996-05-31 1998-01-13 Ilekis; John V. Epidermal growth factor receptor-like gene product and its uses
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP4632543B2 (ja) 1998-12-21 2011-02-16 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 切断ｖｅｇｆ−ｄの抗体及びその利用法
NZ517372A (en) 1999-07-29 2004-04-30 Medarex Inc Human monoclonal antibodies to HER2/neu
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
WO2001077342A1 (fr) * 2000-04-11 2001-10-18 Genentech, Inc. Anticorps multivalents et leurs utilisations
KR100480985B1 (ko) 2000-05-19 2005-04-07 이수화학 주식회사 표피 성장 인자 수용체에 대한 사람화된 항체
EP1170011A1 (fr) 2000-07-06 2002-01-09 Boehringer Ingelheim International GmbH Nouvelle utilisation des inhibiteurs de facteur de croissance épidermique
AU9500201A (en) 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists

Also Published As

Publication number Publication date
MXPA03011365A (es) 2005-03-07
EP1417232A2 (fr) 2004-05-12
CZ200438A3 (cs) 2004-06-16
AU2002345673B2 (en) 2007-04-26
HK1064685A1 (en) 2005-02-04
EP1417232A4 (fr) 2005-04-27
US7247301B2 (en) 2007-07-24
HUP0600225A2 (hu) 2006-06-28
NZ530212A (en) 2006-09-29
RU2004100834A (ru) 2005-03-27
CN1610695A (zh) 2005-04-27
EP1417232B1 (fr) 2014-12-03
WO2002100348A8 (fr) 2003-04-10
IL159225A (en) 2009-09-01
CN1966525A (zh) 2007-05-23
JP4298498B2 (ja) 2009-07-22
JP2005501529A (ja) 2005-01-20
WO2002100348A3 (fr) 2003-02-27
BRPI0210405B1 (pt) 2018-11-27
KR20040016883A (ko) 2004-02-25
CA2450285C (fr) 2016-08-02
CN100497389C (zh) 2009-06-10
KR100945108B1 (ko) 2010-03-02
CA2450285A1 (fr) 2002-12-19
RU2335507C2 (ru) 2008-10-10
WO2002100348A2 (fr) 2002-12-19
US20030091561A1 (en) 2003-05-15
BR0210405A (pt) 2005-04-19
BRPI0210405B8 (pt) 2021-05-25
HUP0600225A3 (en) 2010-01-28
KR20090125840A (ko) 2009-12-07
JP2009148282A (ja) 2009-07-09

Similar Documents

Publication Publication Date Title
HUP0600225A3 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
HK1203521A1 (en) Antibodies to nsulin-like growth factor receptor
EP1343820A4 (fr) Anticorps en chaine simple de recepteur de facteur de croissance anti-epidermique humain
IL161705A0 (en) Human monoclonal antibodies to dendritic cells
HK1065051A1 (en) Human monoclonal antibodies to fc alpha receptor (cd89)
EP1519747A4 (fr) Anticorps monoclonaux humains de l'antigene d'enveloppe prostatique specifique (psma)
TWI367102B (en) Therapeutic human anti-il-1r1 monoclonal antibody
CY2008003I1 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
MY145214A (en) Pharmaceutical preparation containing an antibody for the epidermal growth factor (egf) receptor
IL166244A0 (en) Super humanized antibodies
HU230006B1 (en) Antagonistic anti-htnfsf13b human antibodies
EP1467756A4 (fr) Procedes d'utilisation d'anticorps anti-muc18
IL160998A0 (en) Human tissue factor antibodies
EP1570057A4 (fr) Anticorps du recepteur du facteur de croissance autocrine et methodes
AU2003277832A8 (en) Humanized tissue factor antibodies
EP1446416A4 (fr) Anticorps monoclonaux specifiques de tumeur
AU2001281099A1 (en) Production of human monoclonal antibodies
SI0979246T1 (sl) Humana monoklonska protitelesa za receptor epidermalnega rastnega faktorja
ZA200201347B (en) Human monoclonal antibodies to HER2/neu.
GB0017139D0 (en) Human monoclonal antibodies
GB0016824D0 (en) Human monoclonal antibodies
GB0325391D0 (en) Human monoclonal antibodies
GB0121727D0 (en) Monoclonal antibodies